ReviewNaunyn-Schmiedeberg's archives of pharmacology2021
Efficacy of synthetic glucocorticoids in COVID-19 endothelites.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- The efficacy and safety of corticosteroids in treating severe COVID-19 patients: A meta-analysis with trial sequential analysis.Pakistan journal of medical sciences · 2025Review
- Sensitive and selective silver nanoparticle-based fluorescence sensor for corticosteroid determination in pharmaceutical formulations.BMC chemistry · 2025Article
- Clinical Implications of COVID-19-Related Endothelial Dysfunction.JACC. Advances · 2024Review
- Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study.Frontiers in pharmacology · 2024Article
- Impact of COVID-19 on Cardiovascular Disease.Viruses · 2023Review
- Shared miRNA landscapes of COVID-19 and neurodegeneration confirm neuroinflammation as an important overlapping feature.Frontiers in molecular neuroscience · 2023Article
- Pregnancy and COVID-19.Journal of clinical medicine · 2022Review
- Review
- Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.International journal of molecular sciences · 2022Article
- Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.Journal of reproductive immunology · 2022Review
- Multi-omic approach to identify risk markers specific to COVID-19.EBioMedicine · 2022Article
- Vascular endotheliitis associated with infections: Its pathogenetic role and therapeutic implication.Biochemical pharmacology · 2022Review
- A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?Immunologic research · 2022Review
- Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.Molecular biology reports · 2022Article
- Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Review
- Logistics management provides greater efficiency, governance and compliance.International journal of clinical pharmacy · 2021Article
- Commentary of the mRNA vaccines COVID-19.Asian journal of pharmaceutical sciences · 2021Article
- The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.Wiener klinische Wochenschrift · 2021Review
- Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.Wiener klinische Wochenschrift · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since March 2020, the world has been fighting a global pandemic caused by a new coronavirus SARS-CoV-2 (COVID-19). SARS-CoV-2 is responsible for severe acute respiratory syndrome, an airway disease that can be severe and fatal in a percentage of cases. Patients with severe COVID-19 can develop extrapulmonary lesions, with renal, hepatic, cardiac, neurological, and tissue involvement that can cause further severe complications. On December 21, 2021, the European Medicines Agency (EMA) authorized the marketing of the first COVID-19 vaccine. However, several randomized trials are ongoing to find effective, safe, and widely available treatments. The most severe stages of COVID-19 infection are characterized by a multi-system inflammatory state induced by a cytokine storm causing multi-organ injury. Epidemiologic evidence has shown that glucocorticoids (GCs), particularly dexamethasone, are used in severe, hospitalized patients with COVID-19 with good therapeutic benefit. COVID-19 can also damage the endothelial system, causing microcirculatory disturbances and consequently leading to functional organ disorders. The combination of endothelial dysfunction with a generalized inflammatory state may contribute to the general pro-coagulative state described in patients with COVID-19 with increased risk of venous and arterial occlusions. The aim of this article is to describe the therapeutic utility of GCs in stabilizing the vascular endothelial barrier in COVID-19 infection. Indeed, we believe that the stabilization of the endothelial barrier and the anti-inflammatory effect of GCs could be the main effect underlying the therapeutic efficacy in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.